| Date | Title | | | 05/20/13 | ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index| SAN DIEGO--(BUSINESS WIRE)--May. 20, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced
that it has been selected for addition to the NASDAQ Biotechnology Index
(NASDAQ: ^NBI) effective prior to today’s market open.
The NASDAQ Biotechnology Index is designed to track the performance ... |
|  | | 05/20/13 | ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--May. 20, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the
completion of an underwritten public offering of 9,200,000 shares of its
common stock, including 1,200,000 shares sold pursuant to the full
exercise of an option to purchase additional shares previously granted
to the underwriters. All of the shares were offered by ACADIA at a price
to the public of $12.50 per share. The gross proceeds from this off... |
| | | 05/15/13 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--May. 15, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing
of an underwritten public offering of 8,000,000 shares of its common
stock, offered at a price to the public of $12.50 per share. The gross
proceeds from this offering to ACADIA are expected to be $100 million,
before deducting underwriting discounts and commissions and other
estimated offering expenses payable by ACADIA. ACADIA has granted ... |
| | | 05/14/13 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--May. 14, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it
intends to offer and sell, subject to market and other conditions,
shares of its common stock in an underwritten public offering. There can
be no assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Jefferies LLC and Cowen and Company, LLC are acting as the joint
book-ru... |
| | | 05/07/13 | ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May. 7, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its unaudited financial results for the first quarter ended
March 31, 2013.
ACADIA reported a net loss of $6.1 million, or $0.08 per common share,
for the first quarter of 2013 compared... |
| | | 04/30/13 | ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013| ACADIA to Host Conference Call and Webcast on Tuesday, May 7, 2013,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Apr. 30, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its unaudited financial results for the
first quarter ended March 31, 201... |
| | | 04/25/13 | ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013| SAN DIEGO--(BUSINESS WIRE)--Apr. 25, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 12th Annual Needham
Healthcare Conference on Tuesday, April 30, 2013, at 8:00 a.m. Eastern
Time at The Westin New York Grand Central Hotel in New York City.
... |
| | | 04/11/13 | ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA| Single Pivotal Phase III -020 Study and Other Supportive Data
Sufficient for Future NDA Filing for the Treatment of Parkinson’s
Disease Psychosis
Conference Call and Webcast to Be Held Today, April 11, 2013, at 8:00
am Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Apr. 11, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurolo... |
| | | 03/20/13 | ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting| SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced
that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou
Ruvo Center for Brain Health, presented detailed results today from
ACADIA’s pivotal Phase III -020 Study with pimavanserin in pati... |
| | | 03/13/13 | ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013| SAN DIEGO--(BUSINESS WIRE)--Mar. 13, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 25th Annual ROTH Conference on Tuesday, March 19, 2013, at 10:00 a.m. Pacific Time at The Ritz-Carlton in Laguna Niguel.
A live webcast of ACADIA's presentation will be accessible on the company's website, www.... |
| | | 03/12/13 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012| SAN DIEGO--(BUSINESS WIRE)--Mar. 12, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its financial results for the fourth quarter and year ended
December 31, 2012.
ACADIA reported a net loss of $6.8 million, or $0.11 per common share,
for the fourth quarter of 201... |
| | | 03/05/13 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013|
ACADIA to Host Conference Call and Webcast on Tuesday, March 12,
2013, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its financial results for the fourth
quarter and year e... |
| | | 02/25/13 | ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013| SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the Cowen and Company 33rd
Annual Health Care Conference on Monday, March 4, 2013, at 1:30 p.m.
Eastern Time at the Boston Marriott Copley Place.
A live we... |
| | | 02/05/13 | ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013| SAN DIEGO--(BUSINESS WIRE)--Feb. 5, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced
that it will present at the 15th Annual BIO CEO & Investor
Conference on Tuesday, February 12, 2013, at 10:00 a.m. Eastern Time at
The Waldorf=Astoria Hotel in New York City.
A live ... |
| | | 01/22/13 | ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors| SAN DIEGO--(BUSINESS WIRE)--Jan. 22, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced the election of Stephen R. Biggar, M.D., Ph.D., to its board
of directors. Dr. Biggar will fill a vacancy on ACADIA’s board and serve
as a Class II director. The terms of the Class II directors ... |
| | | 12/20/12 | ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program|
Award Will Advance ACADIA’s Selective ER-Beta Agonist as a
Potential New Neuroprotective MS Therapy through Collaborative Research
with UCLA
SAN DIEGO--(BUSINESS WIRE)--Dec. 20, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will receive funding from Fast... |
| | | 12/12/12 | ACADIA Pharmaceuticals Announces $86 Million Equity Financing|
--Proceeds to Support Completion of Pimavanserin Phase III
Program--
SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced a private placement equity financing pursuant to which ACADIA
will receive gross proceeds of $86.4 million from... |
| | | 12/12/12 | ACADIA Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference Today, December 12, 2012| SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced
that it will present at the Oppenheimer 23rd Annual
Healthcare Conference later today, Wednesday, December 12, 2012, at 3:55
p.m. Eastern Time at The Waldorf=Astoria Hotel in New York City.
... |
| | | 11/27/12 | ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial|
Pimavanserin Demonstrates Highly Significant Antipsychotic Efficacy
and Maintenance of Motor Control in Parkinson’s Patients
Significant Improvements Also Observed in All Secondary and
Exploratory Measures
Conference Call and Webcast to Be Held Today, November 27, 2012, at
8:00 am Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Nov. 27, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced successful
top-lin... |
| | | 11/26/12 | ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III Pimavanserin Parkinson’s Disease Psychosis Trial| SAN DIEGO--(BUSINESS WIRE)--Nov. 26, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will host a conference call and webcast at 8:00 a.m.
Eastern Time on Tuesday, November 27, 2012 to present the top-line
results from its pivotal Phase III trial with pimavanserin in patie... |
| | | 11/05/12 | ACADIA Pharmaceuticals Reports Third Quarter 2012 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its unaudited financial results for the third quarter ended
September 30, 2012.
ACADIA reported a net loss of $2.4 million, or $0.04 per common share,
for the third quarter of 2012... |
| | | 10/29/12 | ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 5, 2012|
ACADIA to Host Conference Call and Webcast on Monday, November 5,
2012, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its unaudited financial results for the
third quarter ended S... |
| | | 09/05/12 | ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis|
Top-Line Data Expected in November 2012
SAN DIEGO--(BUSINESS WIRE)--Sep. 5, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced the completion of enrollment in its ongoing pivotal Phase III
trial with pimavanserin in patients with Parkinson’s disease psychosis
(PDP). ... |
| | | 08/29/12 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--Aug. 29, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the following investor conferences:
The Stifel Nicolaus Healthcare Conference on Wednesday, September 5,
2012, at 3:50 p.m. Eastern Time at the Four S... |
| | | 08/08/12 | ACADIA Pharmaceuticals Reports Second Quarter 2012 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its unaudited financial results for the second quarter ended
June 30, 2012.
ACADIA reported a net loss of $5.4 million, or $0.10 per common share,
for the second quarter of 2012 co... |
| | | 08/01/12 | ACADIA Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 8, 2012|
ACADIA to Host Conference Call and Webcast on Wednesday, August 8,
2012, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Aug. 1, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its unaudited financial results for the
second quarter... |
| | | 07/09/12 | ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer’s Disease Psychosis| SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced results of preclinical studies, which suggest that
pimavanserin, ACADIA’s proprietary product candidate currently in Phase
III development for Parkinson’s disease psychosis, also may have
... |
| | | 07/09/12 | ACADIA Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference on July 13, 2012| SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 7th Annual JMP
Securities Healthcare Conference on Friday, July 13, 2012, at 11:00 a.m.
Eastern Time at The Peninsula Hotel in New York City.
A live web... |
| | | 05/15/12 | ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012| SAN DIEGO--(BUSINESS WIRE)--May. 15, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will host a live webcast of its Educational Program on
Parkinson’s Disease Psychosis to be held with analysts and investors in
New York City on Tuesday, May 22, 2012, from 12:00 p.m. to ... |
| | | 05/08/12 | ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May. 8, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its unaudited financial results for the first quarter ended
March 31, 2012.
ACADIA reported a net loss of $6.2 million, or $0.12 per common share,
for the first quarter of 2012 com... |
| | | 05/01/12 | ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012|
ACADIA to Host Conference Call and Webcast on Tuesday, May 8, 2012,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 1, 2012--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will report its unaudited financial results for the
first quarter ende... |
| | | 04/13/12 | ACADIA Pharmaceuticals to Present at the 19th
Annual Future Leaders in the Biotech Industry Conference on April 20,
2012| SAN DIEGO, Apr 13, 2012 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 19th Annual Future
Leaders in the Biotech Industry Conference on Friday, April 20, 2012, at
11:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York
City.... |
| | | 03/28/12 | ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012| SAN DIEGO--(BUSINESS WIRE)--Mar. 28, 2012--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 11th Annual Needham
Healthcare Conference on Tuesday, April 3, 2012, at 9:20 a.m. Eastern
Time at The New York Palace Hotel in New York City.
A live we... |
| | | 03/27/12 | ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease| SAN DIEGO--(BUSINESS WIRE)--Mar. 27, 2012--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it has been awarded a new grant from The Michael J. Fox
Foundation (MJFF) for the further development of Nurr1-RXR selective
agonists for the treatment of Parkinson’s disease. The grant of ... |
| | | 03/06/12 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011| SAN DIEGO--(BUSINESS WIRE)--Mar. 6, 2012--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its financial results for the fourth quarter and year ended
December 31, 2011.
ACADIA reported a net loss of $5.3 million, or $0.10 per common share,
for the fourth quarter of 2011... |
| | | 03/05/12 | ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.| SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2012--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it has extended its drug discovery and development
collaboration with Allergan, Inc. (NYSE: AGN). The collaboration is
currently focused on the discovery of new therapeutics for glaucoma and... |
| | | 02/29/12 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--Feb. 29, 2012--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the following investor
conferences:
The Cowen and Company 32nd Annual Health Care Conference on
Wednesday, March 7, 2012, at 10:00 a.... |
| | | 02/28/12 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012|
ACADIA to Host Conference Call and Webcast on Tuesday, March 6, 2012,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 28, 2012--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its financial results for the fourth
quarter and year... |
| | | 02/06/12 | ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012| SAN DIEGO--(BUSINESS WIRE)--Feb. 6, 2012--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the 14th Annual BIO
CEO & Investor Conference on Monday, February 13, 2012, at 9:30 a.m.
Eastern Time at The Waldorf=Astoria Hotel in New York City.
... |
| | | 01/30/12 | ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors| SAN DIEGO--(BUSINESS WIRE)--Jan. 30, 2012--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced the election of William (Bill) M. Wells to its board of
directors.
“We are very pleased to have Bill join ACADIA’s board,” said Uli
Hacksell, Ph.D., ACADIA’s Chief Execut... |
| | | 12/07/11 | ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011| SAN DIEGO--(BUSINESS WIRE)--Dec. 7, 2011--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Oppenheimer 22nd
Annual Healthcare Conference on Wednesday, December 14, 2011, at 11:05
a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City.
... |
| | | 11/09/11 | ACADIA Pharmaceuticals Reports Third Quarter 2011 Financial Results| SAN DIEGO, Nov 09, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2011.
ACADIA reported a net loss of $5.1 million, or $0.10 per common share, for the third quarter of 2011 compared to a net loss of $4.2 million, or $0.11 ... |
| | | 11/07/11 | ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma| --FDA Accepts Investigational New Drug Application for AM-831--
SAN DIEGO, Nov 07, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, ... |
| | | 11/02/11 | ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011| ACADIA to Host Conference Call and Webcast on Wednesday, November 9, 2011, at 5:00 p.m. Eastern Time
SAN DIEGO, Nov 02, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2011 on Wednesday, November 9, ... |
| | | 09/21/11 | ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities
Healthcare Conference on September 28, 2011| SAN DIEGO, Sep 21, 2011 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Sixth Annual JMP Securities
Healthcare Conference on Wednesday, September 28, 2011, at 12:00 p.m.
Eastern Time at The St. Regis Hotel in New York City.
A live w... |
| | | 09/06/11 | ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011| SAN DIEGO, Sep 06, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011, at 4:30 p.m. Eastern Time at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACADIA's presentation ... |
| | | 08/10/11 | ACADIA Pharmaceuticals Reports Second Quarter 2011 Financial Results| SAN DIEGO, Aug 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2011.
ACADIA reported a net loss of $6.6 million, or $0.12 per common share, for the second quarter of 2011 compared to a net loss of $4.3 million, or $0.11 per... |
| | | 08/03/11 | ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011| ACADIA to Host Conference Call and Webcast on Wednesday, August 10, 2011, at 5:00 p.m. Eastern Time
SAN DIEGO, Aug 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2011 on Wednesday, August 10, 2011, af... |
| | | 05/17/11 | ACADIA Pharmaceuticals Awarded Grant from National Institutes of Health for the Development of Novel ER-beta Agonists| SAN DIEGO, May 17, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a grant from the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH), for the development of novel estrogen receptor beta (ER-beta) agonist... |
| | | 05/10/11 | ACADIA Pharmaceuticals Reports First Quarter 2011 Financial Results| SAN DIEGO, May 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2011.
ACADIA reported a net loss of $5.8 million, or $0.12 per common share, for the first quarter of 2011 compared to a net loss of $5.5 million, or $0.14 per... |
| | | 05/04/11 | ACADIA Pharmaceuticals to Present at the Tenth Annual JMP Securities Research Conference on May 11, 2011| SAN DIEGO, May 04, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Tenth Annual JMP Securities Research Conference on Wednesday, May 11, 2011, at 1:30 p.m. Pacific Time at The Ritz-Carlton Hotel in San Francisco.
A live webcast of ACADIA's presentation will be accessi... |
| | | 05/03/11 | ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011| ACADIA to Host Conference Call and Webcast on Tuesday, May 10, 2011, at 5:00 p.m. Eastern Time
SAN DIEGO, May 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2011 on Tuesday, May 10, 2011, after the ... |
| | | 04/01/11 | ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.| SAN DIEGO, Apr 01, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc. (NYSE: AGN). The collaboration is focused on the discovery of innovative new therapeutics for glaucoma and other ophthalmic indications and w... |
| | | 03/29/11 | ACADIA Pharmaceuticals to Present at the Tenth Annual Needham Healthcare Conference on April 5, 2011| SAN DIEGO, Mar 29, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Tenth Annual Needham Healthcare Conference on Tuesday, April 5, 2011, at 8:40 a.m. Eastern Time at The New York Palace Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible... |
| | | 03/10/11 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010| SAN DIEGO, Mar 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2010.
ACADIA reported net income of $29.1 million, or $0.74 per common share, for the fourth quarter of 2010 compared to a net loss of $(8.7) million, or $(... |
| | | 03/03/11 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011| ACADIA to Host Conference Call and Webcast on Thursday, March 10, 2011, at 5:00 p.m. Eastern Time
SAN DIEGO, Mar 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2010 on Thursday, March 10, 2011, aft... |
| | | 02/08/11 | ACADIA Pharmaceuticals to Present at the Thirteenth Annual BIO CEO & Investor Conference on February 15, 2011| SAN DIEGO, Feb 08, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Thirteenth Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011, at 8:30 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACADIA's presentation will be a... |
| | | 01/10/11 | ACADIA Pharmaceuticals Announces $15 Million Private Placement| --Proceeds to Support Advancement of Pimavanserin Phase III Program--
SAN DIEGO, Jan 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterp... |
| | | 11/09/10 | ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel Nurr1-RXR Agonists to Treat Parkinson's Disease| SAN DIEGO, Nov 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a grant from The Michael J. Fox Foundation (www.michaeljfox.org) for the development of novel Nurr1-RXR agonists for the treatment of Parkinson's disease. The grant of $300,000 was awarded under the Foundati... |
| | | 11/09/10 | ACADIA Pharmaceuticals Reports Third Quarter 2010 Financial Results| SAN DIEGO, Nov 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2010.
ACADIA reported a net loss of $4.2 million, or $0.11 per common share, for the third quarter of 2010 compared to a net loss of $8.7 million, or $0.23 ... |
| | | 11/02/10 | ACADIA Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 9, 2010| ACADIA to Host Conference Call and Webcast on Tuesday, November 9, 2010, at 5:00 p.m. Eastern Time
SAN DIEGO, Nov 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2010 on Tuesday, November 9, 2010... |
| | | 10/28/10 | ACADIA Pharmaceuticals Enters Agreement with Biovail to Conclude Collaboration and Regain North American Rights to Pimavanserin| ACADIA Now Holds Worldwide Rights; Receives $8.75 Million Payment to Continue Ongoing Phase III Trials in Parkinson's Disease Psychosis
ACADIA Conference Call Scheduled for Today, October 28, at 9:00 A.M. Eastern Time
SAN DIEGO, Oct 28, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has entered into an agreement with Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE and TS... |
| | | 09/22/10 | ACADIA Pharmaceuticals to Present at the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010| SAN DIEGO, Sep 22, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Fifth Annual JMP Securities Healthcare Conference on Tuesday, September 28, 2010, at 8:30 a.m. Eastern Time at The New York Palace Hotel in New York City.
A live webcast of ACADIA's presentation will b... |
| | | 09/07/10 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO, Sep 07, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:
The Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 14, 2010, at 12:30 p.m. Eastern Time at The New York Palace Hotel in New York City.
... |
| | | 08/09/10 | ACADIA Pharmaceuticals Reports Second Quarter 2010 Financial Results| SAN DIEGO, Aug 09, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the second quarter
ended June 30, 2010.
ACADIA reported a net loss of $4.3 million, or $0.11 per common share,
for the second quarter of 2010 compared to... |
| | | 08/02/10 | ACADIA Pharmaceuticals to Announce Second Quarter 2010 Financial
Results on August 9, 2010| ACADIA to Host Conference Call and Webcast on Monday, August 9, 2010,
at 5:00 p.m. Eastern Time
SAN DIEGO, Aug 02, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the second quarter ended June 30, 2010... |
| | | 07/29/10 | ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial
with Pimavanserin for Parkinson's Disease Psychosis| SAN DIEGO, Jul 29, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it has initiated a new Phase III trial designed to
evaluate the efficacy, tolerability and safety of pimavanserin as a
treatment for patients with Parkinson's disease psychosis (PDP).
... |
| | | 06/02/10 | ACADIA Pharmaceuticals To Present at the Ninth Annual Needham
Healthcare Conference on June 9, 2010| SAN DIEGO, Jun 02, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Ninth Annual Needham
Healthcare Conference on Wednesday, June 9, 2010 at 3:20 p.m. Eastern
Time at The New York Palace Hotel in New York City.
A live webcast of A... |
| | | 05/10/10 | ACADIA Pharmaceuticals Reports First Quarter 2010 Financial Results| SAN DIEGO, May 10, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the first quarter
ended March 31, 2010.
ACADIA reported a net loss of $5.5 million, or $0.14 per common share,
for the first quarter of 2010 compared to a... |
| | | 05/05/10 | ACADIA Pharmaceuticals to Present at the Ninth Annual JMP Securities
Research Conference on May 12, 2010| SAN DIEGO, May 05, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Ninth Annual JMP Securities
Research Conference on Wednesday, May 12, 2010 at 11:00 a.m. Pacific
Time at The Ritz-Carlton Hotel in San Francisco.
A live webcast o... |
| | | 05/03/10 | ACADIA Pharmaceuticals to Announce First Quarter 2010 Financial
Results on May 10, 2010| ACADIA to Host Conference Call and Webcast on Monday, May 10, 2010,
at 5:00 p.m. Eastern Time
SAN DIEGO, May 03, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the first quarter ended March 31, 2010 ... |
| | | 04/14/10 | Dr. Joseph Friedman to Present Data From ACADIA Pharmaceuticals' First Phase III Trial With Pimavanserin for Parkinson's Disease Psychosis at the 62nd American Academy of Neurology Annual Meeting| SAN DIEGO, Apr 14, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Joseph H. Friedman, MD, will present data from ACADIA's previously reported Phase III trial (the -012 Study) with pimavanserin for Parkinson's disease psychosis (PDP) at the 62nd American Academy of Neurology Annual Meeting on ... |
| | | 03/09/10 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth
Quarter and Year Ended December 31, 2009| SAN DIEGO, Mar 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its financial results for the fourth quarter and year
ended December 31, 2009.
ACADIA reported a net loss of $8.7 million, or $0.23 per common share,
for the fourth quarter of 2009 compared t... |
| | | 03/02/10 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2009
Financial Results on March 9, 2010| ACADIA to Host Conference Call and Webcast on Tuesday, March 9, 2010, at 5:00 p.m. Eastern TimeSAN DIEGO, Mar 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the fourth quarter and year ended December 31, 2... |
| | | 02/01/10 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor
Conference on February 8, 2010| SAN DIEGO, Feb 01, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2010 on Monday, February 8, 2010, at 3:00 p.m. Eastern Time
at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACA... |
| | | 11/09/09 | ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 9, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the third quarter
ended September 30, 2009.
ACADIA reported a net loss of $8.7 million, or $0.23 per common share,
for the third quarte... |
| | | 11/02/09 | ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009|
ACADIA to Host Conference Call and Webcast on Monday, November 9,
2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the third quar... |
| | | 10/20/09 | ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009| SAN DIEGO--(BUSINESS WIRE)--Oct. 20, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIOCOM Investor Conference
2009 on Monday, October 26, 2009 at 2:30 p.m. Pacific Time at the Hyatt
Regency in San Diego.
A live webcast of AC... |
| | | 10/06/09 | ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2009| SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the JMP Securities Healthcare
Focus Conference on Tuesday, October 6, 2009 at 3:00 p.m. Eastern Time
at The New York Palace Hotel in New York City.
... |
| | | 10/06/09 | ACADIA Pharmaceuticals Provides Update on Pimavanserin Collaborative Development Program| SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today provided an update on its Phase III program with pimavanserin for
Parkinson’s disease psychosis (PDP), which is being pursued in
collaboration with Biovail Laboratories International SRL (&... |
| | | 09/01/09 | ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis|
Pimavanserin Misses Primary Endpoint of Antipsychotic Efficacy; Meets
Key Secondary Endpoint of Motoric Tolerability
Conference Call Scheduled for Today, September 1, at 8:00 A.M.
Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Sep. 1, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line
results from the first pivotal Phase III trial with pimavanserin in
patients with Parkinson’s disease psychosis, or P... |
| | | 08/05/09 | ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the second quarter
and six months ended June 30, 2009.
ACADIA reported a net loss of $12.7 million, or $0.34 per common share,
for the ... |
| | | 07/29/09 | ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009| ACADIA to Host Conference Call and Webcast on Wednesday, August 5, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the second quarter ended June 30, 20... |
| | | 06/03/09 | ACADIA Pharmaceuticals to Present at the Eighth Annual Needham Life Sciences Conference on June 10, 2009| SAN DIEGO--(BUSINESS WIRE)--Jun. 3, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Eighth Annual Needham Life
Sciences Conference on Wednesday, June 10, 2009 at 9:30 a.m. Eastern
Time at The New York Palace Hotel in New York City.
... |
| | | 05/13/09 | ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009| SAN DIEGO--(BUSINESS WIRE)--May. 13, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Eighth Annual JMP Securities
Research Conference on Tuesday, May 19, 2009 at 2:30 p.m. Pacific Time
at The Ritz-Carlton Hotel in San Francisco.
... |
| | | 05/11/09 | ACADIA Pharmaceuticals Reports First Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May. 11, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the first quarter
ended March 31, 2009.
ACADIA reported a net loss of $15.0 million, or $0.40 per common share,
for the first quarter ... |
| | | 05/06/09 | ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis| Top-Line Data Expected in the Third Quarter of 2009
SAN DIEGO & TORONTO--(BUSINESS WIRE)--May. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Biovail Corporation
(NYSE:BVF) (TSX:BVF), today announced the completion of enrollment in
the first pivotal Phase III clinical trial of pimavanserin in patients
with Parkinson’s disease psychosis (PDP). Top-line results from this
trial are expected to be announced by the end of the third quarter of
20... |
| | | 05/05/09 | ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009| ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 5, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the first quarter ended March 31, 2009 on... |
| | | 05/04/09 | ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America| Conference Call Scheduled for Today, May 4, 2009, at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 4, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced that it has
established a collaboration with Biovail Laboratories International SRL,
a subsidiary of Biovail Corporation, to co-develop and commercialize
pimavanserin, ACADIA’s proprietary and selective 5-HT2A inverse
agonist, in the United States and Canada. ACADIA retains rights t... |
| | | 03/25/09 | ACADIA Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs| Meiji Seika Granted Rights to Develop and Commercialize Products in Asian Territory; ACADIA Retains All Rights in the Rest of the World
SAN DIEGO--(BUSINESS WIRE)--Mar. 25, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Meiji Seika Kaisha, Ltd.
(TSE:2202) today announced that they have established a collaboration to
develop and commercialize a novel class of pro-cognitive drugs to treat
patients with schizophrenia and related disorders in Japan and several
... |
| | | 03/09/09 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2008| SAN DIEGO--(BUSINESS WIRE)--Mar. 9, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the fourth quarter
and year ended December 31, 2008.
ACADIA reported a net loss of $14.0 million, or $0.38 per common share,
for the fo... |
| | | 03/04/09 | ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009| SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Barclays Capital Global
Healthcare Conference on Wednesday, March 11, 2009, at 9:30 a.m. Eastern
Time at the Loews Miami Beach Hotel in Miami Beach, Florida.... |
| | | 03/02/09 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009| ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Mar. 2, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the fourth quarter and year ended Decemb... |
| | | 02/03/09 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2009 on Tuesday, February 10, 2009, at 10:00 a.m. Eastern
Time at The Waldorf=Astoria Hotel in New York City.
A live webcast o... |
| | | 01/07/09 | ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel ER-beta Agonists for the Treatment of Parkinson’s Disease| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it has been awarded a grant from The Michael J. Fox
Foundation for the development of novel estrogen receptor beta (ER-beta)
agonists for the treatment of Parkinson’s disease. The grant of up to
... |
| | | 11/25/08 | ACADIA Pharmaceuticals to Present at The 20th Annual Piper Jaffray Health Care Conference on December 3, 2008| SAN DIEGO, Nov 25, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at The 20th Annual Piper
Jaffray Health Care Conference on Wednesday, December 3, 2008, at 10:30
a.m. Eastern Time at The New York Palace Hotel in New York City.
A live ... |
| | | 11/05/08 | ACADIA Pharmaceuticals Reports Third Quarter 2008 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the third quarter ended September 30,
2008.
ACADIA reported a net loss of $15.6 million, or $0.42 per common
share, for the third quarter of 2008 compared to a net loss of $16.0
mil... |
| | | 11/03/08 | ACADIA Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008| SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at The Rodman & Renshaw 10th Annual Healthcare
Conference on Tuesday, November 11, 2008, at 11:35 a.m. Eastern Time
at The New York Palace Hotel in New York City.
A live webcast of ACADIA's presen... |
| | | 10/29/08 | ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008| ACADIA to Host Conference Call and Webcast on Wednesday, November
5, 2008, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the third quarter
ended September 30, 2008... |
| | | 10/21/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the following
investor conferences:
-- The BIOCOM Investor Conference 2008 on Tuesday, October 28,
2008, at 3:30 p.m. Pacific Time at the Hyatt Regency in San
Diego.
-- BIO I... |
| | | 09/29/08 | ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the JMP Securities
Healthcare Focus Conference on Monday, October 6, 2008, at 1:00 p.m.
Eastern Time at Le Parker Meridien Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible o... |
| | | 09/05/08 | ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility| SAN DIEGO--(BUSINESS WIRE)--Sept. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it filed a registration statement as required under the terms of its
previously announced Committed Equity Financing Facility (CEFF) with
Kingsbridge Capital Limited.
Under the terms of the CEFF, ACADIA has acces... |
| | | 08/28/08 | ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008| SAN DIEGO, Aug 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at The Thomas Weisel Partners 2008
Healthcare Conference on Thursday, September 4, 2008, at 2:40 p.m.
Eastern Time at the Four Seasons Boston Hotel.
A live webcast of AC... |
| | | 08/05/08 | ACADIA Pharmaceuticals Secures Committed Equity Financing Facility| SAN DIEGO, Aug 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it has entered into a Committed Equity
Financing Facility (CEFF) with Kingsbridge Capital Limited in which
Kingsbridge has committed to provide up to $60 million of capital
during the next three years through the purchase... |
| | | 08/05/08 | ACADIA Pharmaceuticals Announces Second Quarter 2008 Financial Results and Strategic Restructuring| SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the second quarter ended June 30, 2008
and announced a strategic restructuring.
ACADIA will focus on developing a portfolio of its four most
advanced product candidates, consisting o... |
| | | 07/29/08 | ACADIA Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008| ACADIA to Host Conference Call and Webcast on Tuesday, August 5,
2008, at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--July 29, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the second quarter
ended June 30, 2008 on... |
| | | 06/16/08 | ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial| -- Conference Call Scheduled for Today, June 16, 2008, at 8:30
a.m. Eastern Time --
SAN DIEGO--(BUSINESS WIRE)--June 16, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD) today announced results from its Phase IIb trial
with ACP-104 for the treatment of schizophrenia. The study did not
meet its primary endpoint of antipsychotic efficacy or any of the
secondary endpoints. Neither dose of ACP-104 demonstrated improved
efficacy as compared to placebo. The most c... |
| | | 06/04/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--June 4, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The Seventh Annual Needham & Company Biotechnology and Medical
Technology Conference on Wednesday, June 11, 2008, at 1:30
p.m. Eastern Time at ... |
| | | 05/14/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--May 14, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The 2008 Citi Investment Research Global Health Care
Conference on Thursday, May 22, 2008, at 10:30 a.m. Eastern
Time at the Hilton New York i... |
| | | 05/05/08 | ACADIA Pharmaceuticals Announces Election of Laura A. Brege to Board of Directors| SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced the
election of Laura A. Brege to its board of directors. Ms. Brege will
fill a vacancy on the Board and serve as a Class III director. The
terms of the Class III directors expire at the annual meeting of
stockholders in 2... |
| | | 05/05/08 | ACADIA Pharmaceuticals Reports First Quarter 2008 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system (CNS) disorders, today reported
its unaudited financial results for the first quarter ended March 31,
2008.
ACADIA reported a net loss of $16.4 million, or $0.44 per common
share, for the first quarter of 2008 compared to a net loss of $12.6
mil... |
| | | 04/30/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--April 30, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
Deutsche Bank's 33rd Annual Health Care Conference on
Wednesday, May 7, 2008, at 9:30 a.m. Eastern Time at the
InterContinental Boston Hote... |
| | | 04/28/08 | ACADIA Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 5, 2008| ACADIA to Host Conference Call and Webcast on Monday, May 5, 2008,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--April 28, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the first quarter
ended March 31, 2008 on M... |
| | | 04/16/08 | ACADIA Pharmaceuticals to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting| SAN DIEGO--(BUSINESS WIRE)--April 16, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the company will present data from its previously reported Phase II
trial with pimavanserin for Parkinson's disease psychosis (PDP) at the
60th American Academy of Neurology Annual Meeting on April 16, 2008 in
Chica... |
| | | 04/04/08 | ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104, ACP-105 and Its Muscarinic Discovery Program at Experimental Biology 2008 Meeting| SAN DIEGO--(BUSINESS WIRE)--April 4, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the company will present preclinical data on its ACP-104 schizophrenia
program, its ACP-105 Selective Androgen Receptor Modulator (SARM)
program, and its muscarinic discovery program at the Experimental
Biology 2008... |
| | | 03/31/08 | ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis| SAN DIEGO--(BUSINESS WIRE)--March 31, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it has initiated its second Phase III trial designed to evaluate the
safety and efficacy of pimavanserin as a treatment for Parkinson's
disease psychosis (PDP).
"The start of our second Phase III pivotal trial r... |
| | | 03/28/08 | ACADIA Pharmaceuticals to Present at the 8th Annual Fortis Bank Biotechnology Conference| SAN DIEGO, Mar 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The 8th Annual Fortis Bank Biotechnology Conference on Thursday, April 3, 2008, at 10:00 a.m. Western European Time at the Four Seasons Hotel London in London, England.
About ACADIA Pharmaceuticals
ACADI... |
| | | 03/11/08 | ACADIA Pharmaceuticals to Present at Lehman Brothers 11th Annual Global Healthcare Conference| SAN DIEGO--(BUSINESS WIRE)--March 11, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at Lehman Brothers 11th Annual Global Healthcare
Conference on Tuesday, March 18, 2008, at 2:00 p.m. Eastern Time at
the Loews Miami Beach Hotel in Miami Beach, Florida.
A live webcast of ACADIA... |
| | | 03/05/08 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007|
SAN DIEGO--(BUSINESS WIRE)--March 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD),
a biopharmaceutical company utilizing innovative technology to fuel drug discovery
and clinical development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the fourth quarter and year
ended December 31, 2007.
ACADIA reported a net loss of $17.0 million, or $0.46 per common share, for
the fourth quarter of 2007 compared to a n... |
| | | 02/27/08 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 5, 2008| ACADIA to Host Conference Call and Webcast on Wednesday, March 5,
2008, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the fourth quarter
and year ended December ... |
| | | 02/12/08 | ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development| SAN DIEGO, Feb 12, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced the appointment of John J. Kaiser as Vice
President, Strategic Marketing and Commercial Development. Mr. Kaiser
joins ACADIA from Eli Lilly & Co. where he held a variety of marketing
and commercial management positions over a... |
| | | 02/05/08 | ACADIA Pharmaceuticals Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders| New Data Demonstrate Less Increase in Serum Glucose Levels With Pimavanserin Co-Therapy
SAN DIEGO, Feb 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that Murray Rosenthal, D.O., a Fellow of
the American Psychiatric Association, will present data from ACADIA's
pimavanserin Phase II schiz... |
| | | 02/04/08 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2008| SAN DIEGO, Feb 04, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the BIO CEO &
Investor Conference 2008 on Tuesday, February 12, 2008, at 10:15 a.m.
Eastern Time at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible... |
| |
|
